Trimetazidine in the treatment of angina pectoris and other forms of IHD

1. Bultas J. Léč­ba angi­ny pecto­ris. Jak dnes, jak zít­ra? Me­di­cí­na po pro­mo­ci 2004; 5: 14–30.

2. Packer M. Drug The­ra­py: Combi­ned be­ta–adre­nergic and calcium–entry blocka­de in angi­na pecto­ris. N Engl J Med 1989; 320: 709–718.

3. Sa­vo­nitto S, Ardissi­no D, Egstrup K et al. Combi­na­tion the­ra­py with me­topro­lol and ni­fe­de­pi­ne ver­sus mo­nothe­ra­py in pa­tients with stable angi­na pecto­ris. In­ter­na­tio­nal Multi­center Angi­na (IMA­GE) Stu­dy. J Am Coll Cardiol 1996; 27: 311–316.

4. Hra­dec M, Cha­loup­ka V, Sa­cho­vá M. Angi­na treatment Patterns Survey: Sou­čas­ný stav diagnosti­ky a léč­by ne­moc­ných se sta­bil­ní angi­nou pecto­ris v Čes­ké re­pub­li­ce. Cor Va­sa 2003; 45: 173–180.

5. Lo­paschuk GD. Pharma­co­lo­gic ra­tio­na­le for tri­me­ta­zi­di­ne in the treatment of ische­mic heart di­sea­se. Am J Cardio­vasc Drugs 2003; 3(Suppl I): 21–26.

6. Marzilli M. Cardiopro­tecti­ve effects of tri­me­ta­zi­di­ne: a re­view. Curr Med Res Opin 2003; 19: 661–672.

7. Hra­dec J. Lé­ko­vé pro­fi­ly. Tri­me­ta­zi­di­num. 2003; 13: 8–75.

8. Kan­tor P, Lu­cien A, Ko­zak R, Lo­paschuk G. The antiangi­nal drug tri­me­ta­zi­di­ne shifts cardiac energy me­ta­bo­lism from fatty acid oxi­da­tion to glu­co­se oxi­da­tion by inhi­bi­ting mi­to­chondrial long–chain 3–ke­toa­cyl coenzy­me A thio­la­se. Circ Res 2000; 86: 580–588.

9. Marzilli M, Klein WW. Effi­ca­cy and to­le­ra­bi­li­ty of tri­me­ta­zi­di­ne in stable angi­na: a me­ta–ana­ly­sis of rando­mi­zed, double–blind, controlled trials. Cor Art Dis 2003; 14: 171–179.

10. Detry JM, Sellier P, Penna­forte S et al. Tri­me­ta­zi­di­ne: a new concept in the treatment of angi­na. Compa­ri­son with propra­no­lol in pa­tients with stable angi­na. Tri­me­ta­zi­di­ne Euro­pean Multi­center Stu­dy (TEMS) Group. Br J Clin Pharma­col 1994; 37: 279–288.11. Manchanda SC, Krishnaswa­mi S. Combi­na­tion treatment with tri­me­ta­zi­di­ne and diltia­zem in stable angi­na pecto­ris. Heart 1997; 78: 353–357.

12. Le­vy S and Group of South of Fran­ce Investi­ga­tors. Combi­na­tion the­ra­py of tri­me­ta­zi­di­ne with diltia­zem in pa­tients with co­ro­na­ry arte­ry di­sea­se. Am J Cardiol 1995; 76(6): 12B–16B.

13. Mi­chae­li­des PA, Spi­ro­pou­los K, Di­mo­pou­los K et al. Antiangi­nal effi­ca­cy of the combi­na­tion of tri­me­ta­zi­di­ne–propra­no­lol compa­red with mo­no­sorbi­de di­nitra­te–propra­no­lol in pa­tients with stable angi­na. Clin Drug Invest 1997; 13: 8–14.

14. Szwed H, Sa­dowski Z, Eli­kowski W et al. Combi­na­tion treatment in stable effort angi­na using tri­me­ta­zi­di­ne and me­topro­lol. Re­sults of rando­mi­zed, double–blind, multi­centre stu­dy (TRIMPOL II). Eur Hear J 2001; 22: 2267–2274.

15. Hra­dec J, Fi­li­po­vá J. TRI­KET I a II (TRI­me­ta­zi­din v Kom­bi­na­ci s Exis­tu­jí­cí Te­ra­pií) – Vý­sled­ky čes­ké a slo­ven­ské multi­centrické stu­die u 320 ne­moc­ných se sta­bil­ní ná­ma­ho­vou angi­nou pecto­ris. Cor Va­sa 2001; 43: 436–442.

16. Kolbel F, Ba­daV. Tri­me­ta­zi­di­ne in ge­riatric pa­tients with stable angi­na pecto­ris: The Ti­ger Stu­dy. Int J Clin Pract 2003; 57: 867–870.

17. Vi­ta­le C, Wajnga­ten M, Spo­sa­to B et al. Tri­me­ta­zi­di­ne impro­ves left ventri­cu­lar function and quali­ty of li­ve in elderly pa­tients with co­ro­na­ry arte­ry di­sea­se. Eur Heart J 2004; 25: 1814–1821.

18. Lu C, Dabrowski P, Fra­gasso G et al. Effects of tri­me­ta­zi­di­ne on ische­mic left ventri­cu­lar dysfunction in pa­tients with co­ro­na­ry arte­ry di­sea­se. Am J Cardiol 1998; 82: 898–901.

19. Fra­gasso G, Piatti PM, Monti L et al. Short– and long–term be­ne­fi­cial effects of tri­me­ta­zi­di­ne in pa­tients with dia­be­tes and ische­mic cardio­myo­pathy. Am Heart J 2003; 146: 18–25.

20. Sellier P, Broustet JP. Assessment of anti–ische­mic and antiangi­nal effect at trough plasma concentra­tion and sa­fe­ty of tri­me­ta­zi­di­ne MR 35mg in pa­tients with stable angi­na pecto­ris. Am J Cardio­vasc Drugs 2003; 3: 361–369.

21. Ma­kolkin VI, Osadchiy K. Tri­me­ta­zi­di­ne mo­di­fied re­lea­se in the treatment of stable angi­na. Clin Drug Invest 2004; 24: 731–738.

22. Be­lardi­nelli R, Purca­ro A. Effects of tri­me­ta­zi­di­ne on the contracti­le response of chro­ni­cally dysfunctio­nal myocardium to low–do­se do­bu­ta­mi­ne in ische­mic cardio­myo­pathy. Eur Heart J 2001; 23: 2164–2170.

23. Chierchia SL. Tri­me­ta­zi­di­ne and left ventri­cu­lar ischae­mic dysfunction: an overview of cli­ni­cal evi­den­ce. Eur Heart J 2001; 3(Suppl O): 16–20.

24. Fra­gasso G, Piatti PM, Monti L et al. Acu­te effects of he­pa­rin admi­nistra­tion on the ische­mic threshold of pa­tients with co­ro­na­ry arte­ry di­sea­se: eva­lua­tion of the pro­tecti­ve ro­le of the me­ta­bo­lic mo­du­la­tor tri­me­ta­zi­di­ne. J Am Coll Cardiol 2002; 39: 413–419.

25. Tü­ne­rir B, Co­lak Ö, Ala­tas Ö et al. Measu­re­ment of tro­po­nin T to de­tect cardiopro­tecti­ve effect of tri­me­ta­zi­di­ne du­ring co­ro­na­ry arte­ry by­pass grafting. Ann Tho­rac Surg 1999; 68: 2173–2176.

26. Po­lonski L, Dec I, Wojnar R et al. Tri­me­ta­zi­di­ne li­mits the effects of myocardial ischae­mia du­ring percu­ta­neous co­ro­na­ry angioplasty. Curr Med Res Opin 2002; 18(7): 389–396.

27. Haffner SM, Lehto S, Ronne­maa T et al. Morta­li­ty from co­ro­na­ry heart di­sea­se in subjects with ty­pe 2 dia­be­tes and in nondia­be­tic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229–234.

28. Coutinho M, Gerstein HC, Wang Y et al. The re­la­tionship between glu­co­se and in­ci­dent cardio­vascu­lar events: a me­ta­regression ana­ly­sis of published da­ta from 20 stu­dies of 95 783 indi­vi­duals follo­wed for 12.4 years. Dia­be­tes Ca­re 1999; 22(2): 233–240.

29. Bartnik M, Ry­dén L, Ferra­ri R et al. The pre­va­lence of abnormal glu­co­se re­gu­la­tion in pa­tients with co­ro­na­ry arte­ry di­sea­se across Euro­pe. The Euro Heart Survey on dia­be­tes and the heart. Eur Heart J 2004; 25(21): 1880–1890.

30. Pyora­la K, Lehto S, De Bacquer D et al (On be­half of the EUROASPI­RE I and II Groups). Risk factor ma­na­ge­ment in diabe­tic and non–diabe­tic pa­tients with co­ro­na­ry heart di­sea­se. Findings from the EUROASPI­RE I and II surveys. Diabe­to­lo­gia 2004; 47(7): 1257–1265.

31. Hasdai D, Be­har S, Wallentin L et al. A prospecti­ve survey of the cha­racte­ristics, treatments and outco­mes of pa­tients with acu­te co­ro­na­ry syndro­mes in Euro­pe and the Me­di­terra­nean ba­sin; The Euro Heart Survey of Acu­te Co­ro­na­ry Syndro­mes. Eur Heart J 2002; 23(15): 1190–1201.

32. Szwed H, Sa­dowski Z, Pa­chocki R et al. The antiische­mic effects and to­le­ra­bi­li­ty of tri­me­ta­zi­di­ne in co­ro­na­ry diabe­tic pa­tients. A substu­dy from TRIMPOL–1. Cardio­vasc Drugs Ther 1999; 13(3): 217–222.

33. Ro­sa­no GMC, Vi­ta­le C, Spo­sa­to B et al. Tri­me­ta­zi­di­ne impro­ves left ventri­cu­lar function in diabe­tic pa­tients with co­ro­na­ry arte­ry di­sea­se: a double–blind pla­ce­bo–controlled stu­dy. Cardio­vasc Diabe­tol 2003; 2(1): 16–25.